Biomarkers May Predict Unfavorable Neurological Outcome after Mild Traumatic Brain Injury

Area of Science:

• Neurology
• Biomarkers
• Trauma Care

Background:

• Acute brain injury diagnosis and prognosis are critical in emergency departments.
• Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are emerging biomarkers for brain injury.
• Predictive markers are needed to guide treatment for patients with mild traumatic brain injury (Glasgow Coma Scale Score 14-15).

Purpose of the Study:

• To evaluate if initial and repeat serum GFAP and UCH-L1 concentrations predict acute unfavorable neurological outcomes in patients with brain injury.
• To assess the prognostic value of these biomarkers in the early hours following injury.

Main Methods:

• Multi-center observational trial of adult patients with brain injury presenting to the ED.
• Serum GFAP and UCH-L1 levels measured within 6 hours of injury and serially up to 24 hours.
• Enzyme-linked immunosorbent assay (ELISA) used for biomarker quantification.
• Comparison of biomarker levels between patients with and without acute unfavorable neurological outcomes.

Main Results:

• Initial GFAP and UCH-L1 levels were significantly higher in patients with unfavorable outcomes (p=0.026 and p=0.014, respectively).
• Repeat UCH-L1 measurements (6-12 hours post-injury) were also significantly higher in the unfavorable outcome group (p=0.041).
• GFAP levels at repeat testing did not show significant predictive value.

Conclusions:

• Initial serum GFAP and UCH-L1 concentrations are valuable early predictors of acute unfavorable neurological outcomes in brain-injured patients.
• Repeat UCH-L1 measurements may offer additional prognostic information within the first 12 hours post-injury.
• These biomarkers can aid in risk stratification and clinical decision-making for acute brain injury management.